Annovis Bio, Inc.
ANVS
$4.67
$0.020.43%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.64% | -43.89% | -1.83% | 12.92% | 65.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.45% | -19.21% | -19.55% | -35.50% | -70.48% |
| Operating Income | -69.45% | 19.21% | 19.55% | 35.50% | 70.48% |
| Income Before Tax | 42.53% | -23.90% | -418.99% | 73.60% | 14.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.53% | -23.90% | -418.99% | 73.60% | 14.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.53% | -23.90% | -418.99% | 73.60% | 14.12% |
| EBIT | -69.45% | 19.21% | 19.55% | 35.50% | 70.48% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 62.13% | 28.11% | -216.43% | 81.01% | 40.36% |
| Normalized Basic EPS | 62.12% | 28.11% | -216.08% | 81.01% | 40.36% |
| EPS Diluted | 62.01% | 27.93% | 55.39% | 78.65% | 40.36% |
| Normalized Diluted EPS | 62.12% | 28.11% | -222.24% | 81.01% | 40.36% |
| Average Basic Shares Outstanding | 51.71% | 72.33% | 64.06% | 38.99% | 43.98% |
| Average Diluted Shares Outstanding | 51.71% | 72.33% | 61.03% | 38.99% | 43.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |